评估接受主动治疗的实体瘤患者对第三剂 SARS-CoV-2 BNT162b2 mRNA 疫苗的反应。
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment.
机构信息
Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel.
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
出版信息
JAMA Oncol. 2022 Feb 1;8(2):300-301. doi: 10.1001/jamaoncol.2021.6764.
Abstract
This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.
摘要
本队列研究评估了接受急性全身治疗的实体瘤患者接种第三剂 SARS-CoV-2 BNT162b2 疫苗后的短期体液免疫反应。
相似文献
1
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment.评估接受主动治疗的实体瘤患者对第三剂 SARS-CoV-2 BNT162b2 mRNA 疫苗的反应。
JAMA Oncol. 2022 Feb 1;8(2):300-301. doi: 10.1001/jamaoncol.2021.6764.
2
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.接受 BNT162b2 抗 SARS-CoV-2 疫苗第三剂后的免疫原性和安全性在积极治疗中的实体瘤患者：一项前瞻性队列研究。
ESMO Open. 2022 Apr;7(2):100458. doi: 10.1016/j.esmoop.2022.100458. Epub 2022 Mar 11.
3
Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine.在首次接种BNT162b2 mRNA疫苗后早期感染新型冠状病毒2的个体中的抗体反应。
J Infect. 2022 Jan;84(1):94-118. doi: 10.1016/j.jinf.2021.08.008. Epub 2021 Aug 8.
4
Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.肾移植受者中mRNA-1273和BNT162b2新冠病毒mRNA疫苗免疫原性的比较
Transpl Int. 2022 Jan 4;35:10026. doi: 10.3389/ti.2021.10026. eCollection 2021.
5
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
6
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects.BNT162b2 mRNA疫苗的第二剂并未增强既往感染过新冠病毒的受试者体内的新冠病毒中和抗体反应。
Infection. 2022 Apr;50(2):541-543. doi: 10.1007/s15010-021-01680-z. Epub 2021 Aug 3.
7
Increased Serum IgG Antibody, Avidity, and Surrogate Virus Neutralization Response after a Third Dose for the BNT162b2 mRNA Vaccine to SARS-CoV-2.BNT162b2 mRNA疫苗第三剂接种后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的血清IgG抗体、亲和力及替代病毒中和反应增强
J Appl Lab Med. 2022 Jun 30;7(4):995-997. doi: 10.1093/jalm/jfac018.
8
SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.第三剂科兴或辉瑞疫苗加强针后医护人员针对 SARS-CoV-2 的抗体反应。
J Med Virol. 2022 Aug;94(8):3768-3775. doi: 10.1002/jmv.27794. Epub 2022 Apr 23.
9
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.接受那他珠单抗治疗的多发性硬化症患者接种 BNT162b2 mRNA COVID-19 疫苗后的 6 个月体液免疫反应。
Neurol Sci. 2022 May;43(5):2947-2949. doi: 10.1007/s10072-022-05940-0. Epub 2022 Feb 16.
10
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.mRNA SARS-CoV-2 疫苗的第三剂加强了骨髓纤维化患者的刺突特异性抗体和记忆 B 细胞反应。
Front Immunol. 2022 Sep 29;13:1017863. doi: 10.3389/fimmu.2022.1017863. eCollection 2022.
引用本文的文献
1
Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.2019冠状病毒病疫苗接种对癌症患者的影响：安全性、有效性及长期影响
Support Care Cancer. 2025 Aug 4;33(8):753. doi: 10.1007/s00520-025-09783-1.
2
Low booster uptake in cancer patients despite health benefits.尽管有健康益处，但癌症患者的加强针接种率较低。
iScience. 2024 Jul 26;27(9):110596. doi: 10.1016/j.isci.2024.110596. eCollection 2024 Sep 20.
3
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.三剂 mRNA 新冠疫苗接种方案在实体癌患者中产生了合适的免疫原性和令人满意的疗效。
Vaccines (Basel). 2023 May 23;11(6):1017. doi: 10.3390/vaccines11061017.
4
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.加强针接种后的抗体反应对晚期癌症患者 SARS-CoV-2 突破感染和疾病结局的影响：Vax-on-Third 研究的前瞻性分析。
Curr Oncol. 2023 May 17;30(5):5103-5115. doi: 10.3390/curroncol30050386.
5
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
6
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.COVID-19 疫苗接种后泌尿生殖系统癌症患者免疫反应的 12 个月随访：一项前瞻性队列分析。
Oncologist. 2023 Sep 7;28(9):e748-e755. doi: 10.1093/oncolo/oyad067.
7
Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments.在接受不同抗癌治疗的实体瘤患者中，接种SARS-CoV-2 mRNA加强针的体液效应。
Front Oncol. 2023 Feb 22;13:1089944. doi: 10.3389/fonc.2023.1089944. eCollection 2023.
8
Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease.新冠病毒疫苗在恶性疾病患者中的有效性和安全性
Vaccines (Basel). 2023 Feb 20;11(2):486. doi: 10.3390/vaccines11020486.
9
Immunological Findings in a Group of Individuals Who Were Poor or Non-Responders to Standard Two-Dose SARS-CoV-2 Vaccines.一组对标准两剂次严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗反应不佳或无反应者的免疫学发现
Vaccines (Basel). 2023 Feb 16;11(2):461. doi: 10.3390/vaccines11020461.
10
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System.大型美国医疗体系中免疫功能低下个体对 mRNA COVID-19 疫苗接种情况的分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2251833. doi: 10.1001/jamanetworkopen.2022.51833.
Zotero 插件